Enzastaurin Enhances ATRA-induced Differentiation of Acute Myeloid Leukemia Cells.

Ze-Yi Li,Cui Liang,Ming Ding,Xiang-Qin Weng,Yan Sheng,Jing Wu,Hao Lu,Xun Cai
DOI: https://doi.org/10.21203/rs.3.rs-38343/v1
2020-01-01
Abstract:All-trans retinoic acid (ATRA) is considered to be the sole clinically-useful differentiating agent in the treatment of acute myeloid leukemia (AML). However, ATRA has been effective only in acute promyelocytic leukemia (APL) but not other subtypes of AML. Therefore, discovering strategies to sensitize cells to ATRA may lead to the development of ATRA-based treatments in non-APL AML patients. In the present study, a clinically-achievable concentration of enzastaurin enhanced ATRA-induced differentiation in AML cell lines, HL-60 and U937 as well as non-APL AML primary cells. Furthermore, it also restored ATRA sensitivity in ATRA-resistant cell line, HL-60Res. Mechanistically, in all these cell lines, enzastaurin-ATRA (enz-ATRA) co-treatment enhanced the protein levels of PU.1, CCAAT/enhancer-binding protein beta (C/EBP beta) and C/EBP epsilon. The activity of protein kinase C beta (PKC beta) was suppressed by enzATRA treatment in HL-60 and HL-60Res cells. However, another PKC beta-selective inhibitor mimicked the cellular and molecular effects of enzastaurin only in HL-60 cells. Furthermore, in U937 cells, enz-ATRA activated MEK and ERK, and a MEK-specific inhibitor suppressed enz-ATRA-triggered differentiation and reduced the protein levels of PU.1, C/EBP beta and C/EBP epsilon. Enz-ATRA activated Akt in HL-60 and HL-60Res cells. However, an Akt inhibitor blocked enzATRA-triggered differentiation and restored the protein levels of PU.1, C/EBP beta and C/EBP epsilon only in HL-60Res cells. Therefore, PKC beta inhibition, MEK/ERK and Akt activation were involved in enz-ATRA-induced differentiation in HL-60, U937 and HL-60Res cells, respectively, via modulation of the protein levels of C/EBP beta, C/EBP epsilon and PU.1. Taken together, our findings may help to guide novel therapeutic strategies for AML patients.
What problem does this paper attempt to address?